Blandt de co- inficerede patienter stoppede 3% i efavirenz - gruppen og 2% i kontrolgruppen på grund af sygdomme i lever og galdeveje.
Among co-infected patients, 3% of those treated with efavirenz-containing regimens and 2% in the control arm discontinued from the study because of liver or biliary system disorders.